IR783 - - 稳定纳米药物通过合成氧化疗法和表观遗传调制来增强抗癌免疫反应
Jinzhao Liu1,2,3, Meicen Wu1,2,3, Qingyang Lyu1,2,3
1State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|March 28, 2025
概括
这项研究结合了氧化疗法和表观遗传调节,使用纳米药物来增强三阴性乳腺癌治疗. 这种方法有效地激活免疫系统并抑制瘤生长,提供了一个有前途的新免疫疗法策略.
科学领域:
- 在瘤学瘤学.
- 纳米医学是一种纳米医学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 三重阴性乳腺癌 (TNBC) 由于免疫逃避和转移而带来了重大治疗挑战.
- 目前的免疫疗法在TNBC中表现出有限的疗效,通常归因于免疫抑制性瘤微环境.
研究的目的:
- 开发一种新型的纳米配方,用于同时提供β-lapachone (氧化疗法) 和CUDC101 (表观遗传调节),用于TNBC中的协同抗瘤效应.
- 研究这种纳米药物配方在增强抗癌免疫力和克服免疫逃避方面的潜力.
主要方法:
- 通过小分子自我组装形成IR783稳定纳米药物,以同时输送β-lapachone和CUDC101.
- 评估纳米药物诱导的癌细胞亡,免疫细胞死亡和促炎性细胞因子表达.
- 通过调节免疫反应来抑制原发性和远程瘤生长的纳米药物的疗效的评估.
主要成果:
- 通过抑制HDAC,IR783稳定纳米药物通过增强氧化疗法表现出协同抗瘤作用.
- 药物的同时递送诱导了免疫细胞死亡,并促进了亲炎性细胞因子基因表达,重塑了免疫抑制的微环境.
- 这些纳米药物有效地抑制了主要和远程瘤的生长,表明增强了全身抗癌免疫力.
结论:
- 通过一种新的纳米药物输送系统将氧化疗法与表观遗传调制结合起来,为TNBC免疫疗法提供了一个有前途的策略.
- 这种方法有效地克服了免疫逃避,并重塑了瘤微环境,导致强大的抗瘤免疫激活.
- 开发的纳米药物配方为治疗三阴性乳腺癌提供了一种安全有效的方法.
相关概念视频
02:49Cancer Therapies
8.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.5K
02:57Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:27Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81